Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

IRWD vs CPIX vs SUPN vs PRGO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IRWD
Ironwood Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$680M
5Y Perf.-57.1%
CPIX
Cumberland Pharmaceuticals Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$65M
5Y Perf.+30.7%
SUPN
Supernus Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$3.01B
5Y Perf.+116.7%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%

IRWD vs CPIX vs SUPN vs PRGO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IRWD logoIRWD
CPIX logoCPIX
SUPN logoSUPN
PRGO logoPRGO
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$680M$65M$3.01B$1.61B
Revenue (TTM)$362M$42M$777M$4.18B
Net Income (TTM)$151M$-7M$-29M$-1.82B
Gross Margin70.4%82.9%89.4%34.2%
Operating Margin55.3%-17.2%-5.5%-4.1%
Forward P/E3.1x24.1x5.6x
Total Debt$598M$10M$41M$3.97B
Cash & Equiv.$215M$11M$128M$532M

IRWD vs CPIX vs SUPN vs PRGOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IRWD
CPIX
SUPN
PRGO
StockMay 20May 26Return
Ironwood Pharmaceut… (IRWD)10042.9-57.1%
Cumberland Pharmace… (CPIX)100130.7+30.7%
Supernus Pharmaceut… (SUPN)100216.7+116.7%
Perrigo Company plc (PRGO)10021.4-78.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: IRWD vs CPIX vs SUPN vs PRGO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IRWD leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Cumberland Pharmaceuticals Inc. is the stronger pick specifically for growth and revenue expansion. SUPN and PRGO also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
IRWD
Ironwood Pharmaceuticals, Inc.
The Value Play

IRWD carries the broadest edge in this set and is the clearest fit for value and quality.

  • Lower P/E (3.1x vs 5.6x)
  • 41.8% margin vs PRGO's -43.5%
  • +426.5% vs PRGO's -51.2%
  • 38.5% ROA vs PRGO's -19.8%, ROIC 54.0% vs 3.7%
Best for: value and quality
CPIX
Cumberland Pharmaceuticals Inc.
The Growth Play

CPIX is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 17.6%, EPS growth 58.7%, 3Y rev CAGR 2.0%
  • 17.6% revenue growth vs IRWD's -15.7%
Best for: growth exposure
SUPN
Supernus Pharmaceuticals, Inc.
The Income Pick

SUPN is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 0.78
  • 228.4% 10Y total return vs CPIX's -8.1%
  • Lower volatility, beta 0.78, Low D/E 3.9%, current ratio 1.90x
  • Beta 0.78, current ratio 1.90x
Best for: income & stability and long-term compounding
PRGO
Perrigo Company plc
The Income Pick

PRGO is the clearest fit if your priority is dividends.

  • 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Best for: dividends
See the full category breakdown
CategoryWinnerWhy
GrowthCPIX logoCPIX17.6% revenue growth vs IRWD's -15.7%
ValueIRWD logoIRWDLower P/E (3.1x vs 5.6x)
Quality / MarginsIRWD logoIRWD41.8% margin vs PRGO's -43.5%
Stability / SafetySUPN logoSUPNBeta 0.78 vs IRWD's 2.50
DividendsPRGO logoPRGO9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)IRWD logoIRWD+426.5% vs PRGO's -51.2%
Efficiency (ROA)IRWD logoIRWD38.5% ROA vs PRGO's -19.8%, ROIC 54.0% vs 3.7%

IRWD vs CPIX vs SUPN vs PRGO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IRWDIronwood Pharmaceuticals, Inc.
FY 2025
Collaborative Arrangements
99.3%$296M
Collaborative arrangement, collaboration and license agreements
0.6%$2M
Royalty
0.1%$300,000
Collaborative arrangement, other agreements
0.0%$87,000
CPIXCumberland Pharmaceuticals Inc.
FY 2025
Product
74.8%$40M
Product - Vibativ
17.6%$9M
Product - Other
7.6%$4M
SUPNSupernus Pharmaceuticals, Inc.
FY 2025
Product
47.2%$627M
Qelbree
22.9%$305M
GOCOVRI
11.1%$147M
Collaboration Revenue
4.0%$53M
APOKYN
3.6%$48M
Trokendi Xr
3.2%$42M
Oxtellar X R
3.1%$41M
Other (2)
5.0%$66M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B

IRWD vs CPIX vs SUPN vs PRGO — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIRWDLAGGINGPRGO

Income & Cash Flow (Last 12 Months)

IRWD leads this category, winning 5 of 6 comparable metrics.

PRGO is the larger business by revenue, generating $4.2B annually — 99.6x CPIX's $42M. IRWD is the more profitable business, keeping 41.8% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, IRWD holds the edge at +158.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIRWD logoIRWDIronwood Pharmace…CPIX logoCPIXCumberland Pharma…SUPN logoSUPNSupernus Pharmace…PRGO logoPRGOPerrigo Company p…
RevenueTrailing 12 months$362M$42M$777M$4.2B
EBITDAEarnings before interest/tax$201M-$4M$29M$58M
Net IncomeAfter-tax profit$151M-$7M-$29M-$1.8B
Free Cash FlowCash after capex$112M$1M$82M$108M
Gross MarginGross profit ÷ Revenue+70.4%+82.9%+89.4%+34.2%
Operating MarginEBIT ÷ Revenue+55.3%-17.2%-5.5%-4.1%
Net MarginNet income ÷ Revenue+41.8%-17.6%-3.7%-43.5%
FCF MarginFCF ÷ Revenue+31.0%+3.2%+10.6%+2.6%
Rev. Growth (YoY)Latest quarter vs prior year+158.9%-22.0%+38.6%-7.2%
EPS Growth (YoY)Latest quarter vs prior year+2.0%-3.8%+81.0%-56.4%
IRWD leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 3 of 6 comparable metrics.

On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than SUPN's 53.4x.

MetricIRWD logoIRWDIronwood Pharmace…CPIX logoCPIXCumberland Pharma…SUPN logoSUPNSupernus Pharmace…PRGO logoPRGOPerrigo Company p…
Market CapShares × price$680M$65M$3.0B$1.6B
Enterprise ValueMkt cap + debt − cash$1.1B$63M$2.9B$5.1B
Trailing P/EPrice ÷ TTM EPS27.80x-22.77x-76.88x-1.14x
Forward P/EPrice ÷ next-FY EPS est.3.14x24.12x5.56x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple8.81x25.44x53.44x7.42x
Price / SalesMarket cap ÷ Revenue2.30x1.45x4.19x0.38x
Price / BookPrice ÷ Book value/share2.64x2.78x0.55x
Price / FCFMarket cap ÷ FCF5.35x13.39x65.45x11.12x
PRGO leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

IRWD leads this category, winning 5 of 9 comparable metrics.

SUPN delivers a -2.7% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-51 for PRGO. SUPN carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), IRWD scores 6/9 vs PRGO's 4/9, reflecting solid financial health.

MetricIRWD logoIRWDIronwood Pharmace…CPIX logoCPIXCumberland Pharma…SUPN logoSUPNSupernus Pharmace…PRGO logoPRGOPerrigo Company p…
ROE (TTM)Return on equity-29.7%-2.7%-50.7%
ROA (TTM)Return on assets+38.5%-10.5%-2.0%-19.8%
ROICReturn on invested capital+54.0%-8.6%-2.8%+3.7%
ROCEReturn on capital employed+50.9%-6.6%-3.4%+4.3%
Piotroski ScoreFundamental quality 0–96644
Debt / EquityFinancial leverage0.41x0.04x1.35x
Net DebtTotal debt minus cash$382M-$1M-$87M$3.4B
Cash & Equiv.Liquid assets$215M$11M$128M$532M
Total DebtShort + long-term debt$598M$10M$41M$4.0B
Interest CoverageEBIT ÷ Interest expense8.43x-27.86x-7.20x
IRWD leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CPIX leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in SUPN five years ago would be worth $17,801 today (with dividends reinvested), compared to $3,800 for IRWD. Over the past 12 months, IRWD leads with a +426.5% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors CPIX at 37.1% vs IRWD's -26.5% — a key indicator of consistent wealth creation.

MetricIRWD logoIRWDIronwood Pharmace…CPIX logoCPIXCumberland Pharma…SUPN logoSUPNSupernus Pharmace…PRGO logoPRGOPerrigo Company p…
YTD ReturnYear-to-date-2.3%+8.7%+5.7%-13.5%
1-Year ReturnPast 12 months+426.5%-2.1%+69.0%-51.2%
3-Year ReturnCumulative with dividends-60.3%+157.6%+42.1%-58.1%
5-Year ReturnCumulative with dividends-62.0%+62.7%+78.0%-60.1%
10-Year ReturnCumulative with dividends-59.2%-8.1%+228.4%-77.7%
CAGR (3Y)Annualised 3-year return-26.5%+37.1%+12.4%-25.2%
CPIX leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

SUPN leads this category, winning 2 of 2 comparable metrics.

SUPN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than IRWD's 2.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SUPN currently trades 87.6% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIRWD logoIRWDIronwood Pharmace…CPIX logoCPIXCumberland Pharma…SUPN logoSUPNSupernus Pharmace…PRGO logoPRGOPerrigo Company p…
Beta (5Y)Sensitivity to S&P 5002.50x1.09x0.78x1.18x
52-Week HighHighest price in past year$5.78$6.27$59.68$28.44
52-Week LowLowest price in past year$0.53$1.85$29.16$9.23
% of 52W HighCurrent price vs 52-week peak+72.1%+69.0%+87.6%+41.2%
RSI (14)Momentum oscillator 0–10068.467.957.960.9
Avg Volume (50D)Average daily shares traded2.5M1.2M604K3.4M
SUPN leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: IRWD as "Hold", SUPN as "Buy", PRGO as "Hold". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 14.8% for SUPN (target: $60). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.

MetricIRWD logoIRWDIronwood Pharmace…CPIX logoCPIXCumberland Pharma…SUPN logoSUPNSupernus Pharmace…PRGO logoPRGOPerrigo Company p…
Analyst RatingConsensus buy/hold/sellHoldBuyHold
Price TargetConsensus 12-month target$4.80$60.00$20.00
# AnalystsCovering analysts301436
Dividend YieldAnnual dividend ÷ price+9.8%
Dividend StreakConsecutive years of raises10
Dividend / ShareAnnual DPS$1.15
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.4%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

IRWD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics).

Best OverallIronwood Pharmaceuticals, I… (IRWD)Leads 2 of 6 categories
Loading custom metrics...

IRWD vs CPIX vs SUPN vs PRGO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is IRWD or CPIX or SUPN or PRGO a better buy right now?

For growth investors, Cumberland Pharmaceuticals Inc.

(CPIX) is the stronger pick with 17. 6% revenue growth year-over-year, versus -15. 7% for Ironwood Pharmaceuticals, Inc. (IRWD). Ironwood Pharmaceuticals, Inc. (IRWD) offers the better valuation at 27. 8x trailing P/E (3. 1x forward), making it the more compelling value choice. Analysts rate Supernus Pharmaceuticals, Inc. (SUPN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — IRWD or CPIX or SUPN or PRGO?

On forward P/E, Ironwood Pharmaceuticals, Inc.

is actually cheaper at 3. 1x.

03

Which is the better long-term investment — IRWD or CPIX or SUPN or PRGO?

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +78. 0%, compared to -62. 0% for Ironwood Pharmaceuticals, Inc. (IRWD). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — IRWD or CPIX or SUPN or PRGO?

By beta (market sensitivity over 5 years), Supernus Pharmaceuticals, Inc.

(SUPN) is the lower-risk stock at 0. 78β versus Ironwood Pharmaceuticals, Inc. 's 2. 50β — meaning IRWD is approximately 219% more volatile than SUPN relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — IRWD or CPIX or SUPN or PRGO?

By revenue growth (latest reported year), Cumberland Pharmaceuticals Inc.

(CPIX) is pulling ahead at 17. 6% versus -15. 7% for Ironwood Pharmaceuticals, Inc. (IRWD). On earnings-per-share growth, the picture is similar: Cumberland Pharmaceuticals Inc. grew EPS 58. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, SUPN leads at 2. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — IRWD or CPIX or SUPN or PRGO?

Ironwood Pharmaceuticals, Inc.

(IRWD) is the more profitable company, earning 8. 1% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus -6. 3% for CPIX. At the gross margin level — before operating expenses — IRWD leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is IRWD or CPIX or SUPN or PRGO more undervalued right now?

On forward earnings alone, Ironwood Pharmaceuticals, Inc.

(IRWD) trades at 3. 1x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 21. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — IRWD or CPIX or SUPN or PRGO?

In this comparison, PRGO (9.

8% yield) pays a dividend. IRWD, CPIX, SUPN do not pay a meaningful dividend and should not be held primarily for income.

09

Is IRWD or CPIX or SUPN or PRGO better for a retirement portfolio?

For long-horizon retirement investors, Supernus Pharmaceuticals, Inc.

(SUPN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78), +228. 4% 10Y return). Ironwood Pharmaceuticals, Inc. (IRWD) carries a higher beta of 2. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SUPN: +228. 4%, IRWD: -59. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between IRWD and CPIX and SUPN and PRGO?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IRWD is a small-cap quality compounder stock; CPIX is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while IRWD, CPIX, SUPN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IRWD

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 79%
  • Net Margin > 25%
Run This Screen
Stocks Like

CPIX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 49%
Run This Screen
Stocks Like

SUPN

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 19%
  • Gross Margin > 53%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform IRWD and CPIX and SUPN and PRGO on the metrics below

Revenue Growth>
%
(IRWD: 158.9% · CPIX: -22.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.